Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).
about
Update and new approaches in the treatment of Castleman diseaseReview of siltuximab in the treatment of multicentric Castleman's diseaseThe relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.Inflammasome as a Therapeutic Target for Cancer Prevention and Treatment.Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients.Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts--from the point of view of mouse genomics.Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study.Castleman's disease: from basic mechanisms to molecular therapeuticsChronic inflammation in cancer development.Modulation of IL-1β reprogrammes the tumor microenvironment to interrupt oral carcinogenesis.Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.Inflammasomes in carcinogenesis and anticancer immune responses.Targeted therapy in rare cancers--adopting the orphans.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.Siltuximab for multicentric Castleman disease.Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.Use of a claims database to characterize and estimate the incidence rate for Castleman disease.IL-1 receptor accessory protein-Ig/IL-1 receptor type II-Ig heterodimer inhibits IL-1 response more strongly than other IL-1 blocking biopharmaceutical agents.Multicentric Castleman's disease of the central nervous system : evaluation with dynamic susceptibility contrast perfusion magnetic resonance imaging.Biologic Agents in the Treatment of Multicentric Castleman Disease
P2860
Q26740703-79F63F2E-5FFF-49A1-94C2-DA2C2B894F36Q28067246-EA0641CE-AE97-4F1C-A603-4E05D7001270Q33727960-40042EBA-4526-4FF9-8297-B71C2673E9A7Q33888059-171C2991-224F-4849-B07E-DB7565E38CD6Q33920812-FFE489EE-38B8-4595-A563-F9D25A41C2EFQ34081473-E32D1FAF-AE14-470D-A3D7-FED40DA3B43CQ34317938-2EFF8D4F-BE83-450A-9753-1EC126A85A0BQ35584575-64ECDBD2-14AE-4D92-9393-5B6799FDBDD5Q35928265-C3EE05EC-6D47-407F-A1AC-6C02B1F35850Q36527240-29E00271-66FF-4D5D-99D6-13855EDA0A56Q37408163-61AF0FFD-9B97-43E1-90DD-D1910B9A7D63Q37995072-1F0321D1-53D7-4A68-B0D5-217442E1836AQ38042324-B9B32AA1-D8F9-430F-9367-CB715CECF2A9Q38658328-E6B5D7F0-C37F-477A-B0C6-F0A5433B839FQ39146671-6A444973-1F1E-4752-9CD4-FC536620CB2DQ40366614-41DA1C1D-02A0-4E23-8970-F5D580D86F7DQ42008682-ABDFBDED-B6D3-453F-A635-47E7FA9AE042Q43956973-66D0FD36-A3AB-4175-B96F-499339AA8236Q45060751-79972D78-F93C-4F4F-B428-6B7345F9FA8AQ48951886-5D38A371-20BD-4944-942F-ABAED79F9598Q59137206-76AFD1A1-91B8-4D68-933A-C0F3C84DDBD0
P2860
Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@ast
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@en
type
label
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@ast
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@en
prefLabel
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@ast
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@en
P2860
P1476
Successful treatment of Castle ...... eceptor antagonist (Anakinra).
@en
P2093
Hazem El-Osta
P2860
P304
P356
10.1158/1535-7163.MCT-10-0156
P577
2010-05-25T00:00:00Z